Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)

Inclusion criteria

• Adults (age ≥18 years).
• Patients with IBD meeting the following criteria:
• Diagnosis of IBD confirmed by clinical and histological evidence.
• Disease extent (Montreal classification): 1) For Ulcerative Colitis (UC), Extensive colitis (E3): involvement proximal to the splenic flexure; or, Left-sided colitis (E2): involvement distal to the splenic flexure. 2) For Crohn's Disease (CD): Colon-only involvement (L2); or, Ileocolonic involvement (L3).
• Disease duration > 7 years.
• Patients with concommitant Primary Sclerosing Cholangitis, regardless of the extent of colonic involvement and disease duration.
• Written consent from the patient to undergo colonoscopy (signed informed consent).

Exclusion criteria

• Personal history of colorectal cancer (CRC).
• Previous colectomy (partial or complete).
• Coagulopathy preventing biopsy or polypectomy/mucosal resection.
• Colonoscopy performed in the last 6 months.
• Pregnant or lactating women.
• Ulcerative colitis with involvement limited to the rectum or Proctitis (Montreal E1).
• Inadequate colonic preparation due to uncleavable fecal residue during colonoscopy: Boston Bowel Preparation Scale (BBPS) = 0 or 1 in any colon segment.
• Presence of inflammatory activity due to IBD on endoscopy:1) For UC: Endoscopic Mayo Score ≥ 2. 2) For CD: Simplified Endoscopic Activity Score (SES-CD) > 5.
• Incomplete lower digestive endoscopy (failure to reach the cecum).